FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and concerns using IL-1 antagonists for treating gout. Substance of the invention involves using an interleukin 1 (IL-1) antagonist representing a fused protein containing an IL-1 binding part of the outer human domain IL-1RAcP, an IL-1 binding part of the outer human domain IL-1R1 and a multimerisation component, for treating gout. Preferentially, the IL-1 antagonist is protein SEQ ID NO: 10 (Rinolacept).
EFFECT: creation of the product which allows less frequent introduction to reduce symptoms of gout and recurrent attacks, and decrease side effects associated with common methods of treating.
11 cl, 2 ex, 1 tbl
